At a glance
- Originator Kyorin Pharmaceutical
- Class Antibacterials; Quinolones; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 21 May 2001 Profile reviewed but no significant changes made